Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
Consensus approach
Clinical Neurology
610
tau Proteins
cerebrospinal fluid [Amyloid beta-Peptides]
DIAGNOSIS
RECOMMENDATIONS
Cerebrospinal fluid biomarkers
Alzheimer Disease
616
CRITERIA
Humans
ddc:610
cerebrospinal fluid [Peptide Fragments]
clinical report
cerebrospinal fluid biomarkers
consensus approach
Science & Technology
Amyloid beta-Peptides
Featured Articles
9. Industry and infrastructure
[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
diagnosis [Alzheimer Disease]
Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience
Alzheimer's disease
16. Peace & justice
Clinical report
Peptide Fragments
3. Good health
cerebrospinal fluid [Alzheimer Disease]
Alzheimer's disease; cerebrospinal fluid biomarkers; clinical report; consensus approach; harmonization
cerebrospinal fluid [Biomarkers]
cerebrospinal fluid [tau Proteins]
Harmonization
harmonization
Neurosciences & Neurology
Human medicine
Life Sciences & Biomedicine
Alzheimer’s disease
Biomarkers
DOI:
10.1002/alz.12545
Publication Date:
2021-12-22T12:18:10Z
AUTHORS (72)
ABSTRACT
AbstractIntroductionThe current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.MethodsWe obtained a description of (pre‐)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.ResultsThe (pre‐)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DiscussionThis is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (37)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....